An empty chair beside a window in a quiet, bare room — black-and-white film photograph

The Drug the VA Wouldn't Touch for Sixty Years

The room at the Providence VA looks like every other room at every other VA. A reclining chair, a box of tissues, a blood-pressure cuff coiled on the counter, the particular fluorescent flatness of a building run by a federal agency. What is different is what sits in the locked cabinet down the hall: pharmaceutical-grade MDMA, the molecule the government spent sixty years insisting had no medical use at all.

On May 18, the Department of Veterans Affairs began enrolling its first participants in a trial it is running itself. Not funding a university to run, not watching a startup run from a polite distance. The VA, the largest integrated health system in the country, is now the one holding the dose.

What's actually happening

The study has a name as plain as the room: "A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans." It will enroll roughly eighty veterans at the VA Providence Healthcare System in Rhode Island, pulling participants from Providence and from the VA Connecticut Healthcare System in West Haven. Half will receive MDMA paired with a structured, months-long course of therapy. The other half will receive the identical therapy with an active placebo. Everyone is monitored closely; the drug is delivered under medical supervision, in those quiet rooms, with people trained to sit with whatever comes up.

The detail that matters most is the population. PTSD and alcohol use disorder travel together in veterans so often that treating one without the other has long felt like bailing a boat with a hole still in it. Most psychedelic trials screen out the messier cases. This one walks toward them. The VA says it is coordinating with the FDA and intends to share the data, which is a careful way of saying the agency knows exactly what wall this research ran into eighteen months ago.

To understand why a federal trial is a genuinely strange thing, you have to remember that this is the first time the VA has funded psychedelic research since the 1960s. The grant behind it, announced in December 2024, runs about $1.5 million over five years. By government standards that is pocket change. By symbolic standards it is enormous.

The wall this ran into

In August 2024, the FDA declined to approve MDMA-assisted therapy submitted by Lykos Therapeutics, the corporate offshoot of the nonprofit MAPS that had carried this research for decades. The rejection was not a footnote. The agency raised concerns about how durable the benefits were, about safety, and about bias baked into the trial design. An advisory committee had already flagged the obvious problem: when a drug rearranges your perception this completely, nobody stays blind to whether they got the real thing or the sugar pill. The journal Psychopharmacology retracted three papers from an early study. Lykos cut roughly three-quarters of its staff.

"FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine."
— STAT News, October 2025

That headline reads like spin until you sit with it. The Phase 3 results were not nothing. Published in Nature Medicine in 2023, the MAPP2 trial reported that MDMA-assisted therapy reduced PTSD symptoms and functional impairment in a diverse group with moderate to severe PTSD. The science was real. What failed was the scaffolding around it: a small field, run by true believers, that hadn't built the boring institutional rigor regulators demand. The molecule didn't lose. The homework did.

Why the VA, why now

A startup can fold. A field can lose its credibility in a single advisory meeting. What the VA brings is the one thing the psychedelic movement has never had: an institution that cannot be embarrassed out of existence. It is the country's largest health system, it has more PTSD than any other patient population on earth, and it answers to a Congress that has, with rare bipartisan agreement, started pushing it toward exactly this research.

The numbers underneath the politics are not abstract. Veteran suicide has been a national emergency for two decades, and the standard tools — SSRIs approved in the 1990s, talk therapies that ask people to revisit the worst day of their lives over and over — work for some and quietly fail others. When the established answers run out, you either accept the failure rate or you look at what's been sitting on the shelf labeled "no medical use." The VA is choosing to look. It's also expanding psychedelic trials across nine facilities, San Diego among them, which means this is no longer one experiment in Rhode Island. It's a posture.

The long memory of the molecule

There is something worth noticing in the shape of this. A compound gets explored, gets useful, gets swept up in a moral panic, gets buried for half a century, and then comes back through the most conservative door available — a government hospital, a locked cabinet, an active placebo, a clinicaltrials.gov registration number. The rebellion here isn't the drug. The rebellion is the patience. The people who kept this research alive through the decades when saying the word out loud could end a career are not the ones in the room now. The room now belongs to clinicians with IRB approval and federal funding, which is its own kind of vindication for the ones who waited.

None of this means the trial will work. Eighty veterans is a beginning, not a verdict, and the FDA's concerns about blinding don't evaporate because the agency running the study has a flag on the building. But the question has shifted, and that shift is the story. For sixty years the question was whether this molecule should be studied at all. As of May, it's just being studied — carefully, in the plainest room imaginable, by the institution with the least to gain from hype and the most to lose from getting it wrong.

Some things you only understand once the people in charge stop pretending they don't.

Sources:

This is editorial reporting and historical context. Nothing here is medical advice. Psychedelic compounds are controlled substances in most jurisdictions. If you're struggling, talk to a licensed professional.

Back to blog